Geode Capital Management
CELZ icon

Geode Capital Management’s Creative Medical Technology CELZ Stock Holding History

Geode Capital Management’s Portfolio CELZ Stock Details CELZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37.4K Sell
25,799
-12,491
-33% -$27K ﹤0.01% 4291
2026
Q1 		$78.9K Buy
38,290
+9,823
+35% +$19.2K ﹤0.01% 4187
2025
Q4 		$55.8K Buy
28,467
+5,211
+22% +$15.4K ﹤0.01% 4214
2025
Q3 		$76.5K Buy
23,256
+2,380
+11% +$7.38K ﹤0.01% 4194
2025
Q2 		$55.3K Buy
20,876
+2,608
+14% +$5.61K ﹤0.01% 4194
2025
Q1 		$39.7K Buy
18,268
+7,960
+77% +$27.8K ﹤0.01% 4234
2024
Q4 		$24.7K Buy
+10,308
New +$31.2K ﹤0.01% 4361
2023
Q2 		– Sell
-12,422
Closed -$62.1K – 4760
2023
Q1 		$62.1K Buy
12,422
+8,988
+262% +$51K ﹤0.01% 4471
2022
Q4 		$12K Hold
3,434
– – ﹤0.01% 4824
2022
Q3 		$15K Hold
3,434
– – ﹤0.01% 4944
2022
Q2 		$25K Buy
+3,434
New +$55.4K ﹤0.01% 4893

Other funds holding CELZ

Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
GRP
Global Retirement Partners San Rafael, California $6.54B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management's CELZ Position: Q2 2026 in Review

Geode Capital Management reduced its Creative Medical Technology (CELZ) stake by 33% in Q2 2026, selling an estimated $27K and leaving 25,799 shares worth $37.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4291.

Geode Capital Management first reported a position in CELZ in Q2 2022 and has held it in 11 quarters since. The position peaked at $78.9K in Q1 2026. 15 funds tracked by Wall St. Rank hold CELZ as of Q2 2026.

  • Geode Capital Management held 25,799 shares of Creative Medical Technology worth $37.4K as of Q2 2026.
  • Geode Capital Management sold 12,491 Creative Medical Technology shares in Q2 2026, an estimated $27K.
  • Creative Medical Technology made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #4291 holding.
  • Geode Capital Management first reported a position in Creative Medical Technology in Q2 2022 and has held it in 11 quarters since.
  • Geode Capital Management's Creative Medical Technology position peaked at $78.9K in Q1 2026.
  • 15 funds tracked by Wall St. Rank held Creative Medical Technology as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.